Anti-NGF Trials Might Resume With Very Narrow Patient Populations
Executive Summary
FDA’s Arthritis Advisory Committee suggests strictures that could be so strong as to discourage the resumption of clinical trials of Pfizer’s tanezumab, Regeneron’s REGN475 and Janssen’s fulranumab.
You may also be interested in...
Lilly Shows Off R&D Progress With A Pain Franchise Built On New Mechanisms
With galcanezumab for cluster headaches and migraine and tanezumab for osteoarthritis, lower back pain and cancer pain, Lilly soon could have an up-and-running pain franchise bolstering its long-term, internal R&D strategy.
Pfizer/Lilly And J&J Are Readying NGF Inhibitors For Phase III
Pfizer and Lilly plan to resume Phase III testing of their nerve growth factor inhibitor after FDA lifted a partial hold on tanezumab. But J&J is also poised to run new Phase III studies with fulranumab.
Pfizer Plans To Restart Tanezumab Trials In 2014
While questions about the company’s internal reorganization dominated its second-quarter earnings call, Pfizer management also provided some clinical and pipeline updates. Pfizer said the partial clinical hold on its anti-nerve growth factor tanezumab has been lifted and it is preparing to begin Phase III clinical trials in 2014.